Mumbai, December 17, 2024 – Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine
Granules' Ambitious Climate Targets Span Near-Term, Long-Term, and Net-Zero Goals, Aligned with the 1.5°C Pathway Granules India Limited, a leading global pharmaceutical company, has received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals. These targets, aligned with the
Granules India Limited, a leading pharmaceutical company, is thrilled to announce that it has received the Golden Peacock Award for Sustainability. This esteemed award was presented at the Institute of Directors’ Annual Global Convention on Corporate Governance & Sustainability being held in London, UK, and
Granules India inaugurated and launched its packaging facility through its Granules Consumer Health (GCH) step-down subsidiary which is located in Manassas, Virginia, US. The facility is over 79,000 square feet and is equipped with packaging lines and clean rooms to package and ship prescription and
